# Multiple Dose Study in Heart Failure of BAY 1067197

> **NCT02040233** · PHASE2 · COMPLETED · sponsor: **Bayer** · enrollment: 31 (actual)

## Conditions studied

- Heart Failure

## Interventions

- **DRUG:** BAY1067197 (10 mg)
- **DRUG:** BAY1067197
- **DRUG:** Placebo (10 mg)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02040233
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01-28
- **Primary completion:** 2015-01-29
- **Final completion:** 2015-04-02
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2019-06-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02040233

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02040233, "Multiple Dose Study in Heart Failure of BAY 1067197". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT02040233. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*